Alexander DeLuca, M.D.
Addiction, Pain, & Public Health website   
[Home] [Library]  [Slides]  [Search]  [Medline]  [Links]
Statement of Purpose; Privacy policy; Email Confidentiality Policy; Statements of Ownership & Sponsorship; Advertising policy

Predictors of Acamprosate Efficacy:
Results from a Pooled Analysis of Seven European Trials

by Verheul, R., Lehert, P., Geerlings, P.J., Koeter, M.W.J., van den Brink, W.; Psychopharmacology (Berlin); 178: 167-173; 2005
Originally posted: 4/9/2005 [
www.doctordeluca.com/Library/AddictionMeds/predAcampEfficacyEuroMetaAnalysis05.htm]

[Full text of this journal article in PDF format]

ABSTRACT

Rationale:
Acamprosate is a proven effective intervention in the treatment of alcohol dependence. However, acamprosate prevents lapses or relapses only in a minority of patients. An important question, therefore, is whether there is a specific subgroup of patients who respond particularly well to acamprosate.

Objectives:
To identify predictors of acamprosate efficacy. Based upon the available evidence and hypotheses about the mechanisms underlying acamprosatersquos effects on drinking behavior, the following variables were considered to be potential positive predictors: high physiological dependence at baseline, negative family history of alcoholism, late age-of-onset, serious anxiety symptomatology at baseline, severe craving at baseline, and female gender.

Method:
Potential predictors of acamprosatersquos efficacy were analyzed in a pooled analysis of data from seven randomized placebo-controlled trials involving a total of 1485 patients with alcohol dependence. Outcome is measured in terms of cumulative abstinence duration (CAD), continuous abstinence (ABST), and time to first relapse (TFR).

Results:
CAD and ABST were predicted by baseline measures of craving and anxiety, as well as by study and treatment condition. Acamprosate efficacy was not differentially associated with any of the predictor variables. Importantly, the hypotheses were rejected despite the large sample size and sufficient statistical power.

Comment:
The most straight-forward clinical implication of this study is that acamprosate can be considered as a potentially effective pharmacotherapy for all patients with alcohol dependence. The effect size of acamprosate alone is, however, moderate. Some evidence indicates that the combination of acamprosate with naltrexone or disulfiram leads to substantially better outcomes.

 [Full text of this journal article in PDF format]

[END]

 

Dr. DeLuca's Addiction, Pain, and Public Health website

Alexander DeLuca, M.D., FASAM

[Top of Page]

Originally posted:  4/9/2005

All Email to: adeluca@doctordeluca.com 

Statement of Purpose; Privacy policy; Email Confidentiality Policy; Statements of Ownership & Sponsorship; Advertising policy 

Most recently revised: 4/9/2005
Copyright 1998-2004. All rights reserved.

We subscribe to the HONcode principles of the HON Foundation. Click to    This website is in compliance with the HONcode. Pin # = HONConduct911193. Verify HONcode Status.   We subscribe to the HONcode principles of the HON Foundation. Click to